Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
复制标题
DOI：
10.1158/1078-0432.ccr-14-2261
复制
发表时间：
2015-07-15
影响因子：
11.5
通讯作者：
Alimonti, Andrea
中科院分区：
文献类型：
--
作者：
Di Mitri, Diletta;Toso, Alberto;Alimonti, Andrea
肿瘤浸润性髓源性抑制细胞（MDSC）是一种异质性免疫抑制细胞亚群，其阻断T细胞和自然杀伤（NK）细胞的增殖和活性，并促进肿瘤血管发生和进展。最近的证据表明，MDSC在肿瘤中的募集也阻断了由化疗诱导的衰老，促进了化疗耐药性。因此，需要新的治疗方法，可以有效地靶向MDSC招募和癌症中的功能。其中，化疗和免疫治疗的新型组合治疗或诱导外周部位MDSC耗竭的治疗应被考虑。(C)2015年AACR。
Tumor-infiltrating myeloid-derived suppressor cells (MDSC) are a heterogeneous and immunosuppressive cell subset that blocks the proliferation and the activity of both T and natural killer (NK) cells and promotes tumor vasculogenesis and progression. Recent evidences demonstrate that the recruitment of MDSCs in tumors also blocks senescence induced by chemotherapy promoting chemoresistance. Hence, the need of novel therapeutic approaches that can efficiently target MDSC recruitment and function in cancer. Among them, novel combinatorial treatments of chemotherapy and immunotherapy or treatments that induce depletion of MDSCs in peripheral sites should be taken in consideration. (C) 2015 AACR.